TCGA-EW-A6SA-01A-21R-A32P-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 17
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- MYC_TARGETS_V1+0.430
- G2M_CHECKPOINT+0.420
- DNA_REPAIR+0.390
- MYC_TARGETS_V2+0.390
- OXIDATIVE_PHOSPHORYLATION+0.310
- ESTROGEN_RESPONSE_EARLY+0.300
- ESTROGEN_RESPONSE_LATE+0.260
- MITOTIC_SPINDLE+0.210
- SPERMATOGENESIS+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.660
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.580
- INFLAMMATORY_RESPONSE-0.560
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- IL6_JAK_STAT3_SIGNALING-0.490
- KRAS_SIGNALING_UP-0.480
- COAGULATION-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- IL2_STAT5_SIGNALING-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_15_0056_E1_S102 | — | B | 0.945 |
| 2 | 20120289.LumB | — | B | 0.911 |
| 3 | TCGA-BH-A0HW-01A-11R-A034-07 | — | B | 0.906 |
| 4 | BSR_04_0040_A3_S71 | — | B | 0.905 |
| 5 | SRR8518240 | — | E | 0.903 |
| 6 | TCGA-AO-A0J7-01A-11R-A034-07 | — | B | 0.903 |
| 7 | SRR8943005 | — | — | 0.902 |
| 8 | TCGA-EW-A2FW-01A-11R-A17B-07 | — | B | 0.901 |
| 9 | AUR-AE5G-TTM1-A-1-1-R-A742-41 | — | C | 0.896 |
| 10 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.390 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.260 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |